AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bioengineer

Published November 10, 2026

Review links psychedelic therapy to reduced cancer distress - Bioengineer.org

Read the full story at Bioengineer

A new narrative review in Psychedelics synthesizes literature from 2000 to 2025, finding strong evidence for reduced cancer distress but noting.

Post on X

Share this story

Surfaced by 2 Google Alerts

Psychedelics
Psychedelic press release